Articles tagged with Cancer Medication
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A recent study published in JAMA Network Open shows that precision medicine can be a reality for pediatric tumours, identifying genomic anomalies to guide treatment and offer targeted therapies. The TRICEPS project has successfully enrolled 84 patients, leading to better patient management and more effective treatment options.
Researchers found that combining tumor-selective angiotensin blockers with immune checkpoint blockers significantly improves breast cancer treatment in mouse models. The combination treatment normalizes the tumor microenvironment, inducing changes in gene expression and activating immunosupportive pathways.
Researchers have discovered a protein, YTHDF2, that plays a key role in acute myeloid leukaemia (AML), but not in healthy blood cells. This discovery holds promise for novel treatments with fewer side effects than current chemotherapy.
The WINTHER trial successfully matched personalized therapy to 35% of patients with advanced cancer, showing improved overall survival for those with a high degree of matching. The trial's strategy employed RNA expression testing to tailor treatment based on gene expression differences between tumors and normal tissues.
A new zebrafish model has been developed to visualize drug responses at single-cell resolution in live animals, identifying a promising treatment for rhabdomyosarcoma. The model allows for the assessment of combination therapies and direct visualization of drug responses, reducing costs and time required for clinical trials.
A Phase II trial led by the University of Texas MD Anderson Cancer Center reports a 90% response rate for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp. The treatment was effective regardless of prior therapy, and survival rates were relatively high at 59% and 52% at 18 and 24 months, respe...
A clinical trial has shown that targeted therapy tagraxofusp is effective in treating blastic plasmacytoid dendritic-cell neoplasm (BPDCN), a rare and aggressive blood cancer. The therapy, which targets the CD123 protein, has been approved by the FDA for use in BPDCN patients.
Researchers have created a new nanomachine that can deliver specific drugs to parts of the body with tight access barriers, such as pancreatic cancer and brain tumors. The Y-shaped block catiomer is less than one-fifth the size of previous nanoparticles, allowing it to pass through smaller gaps.
Researchers found that over two-thirds of atheists shed their label after a transformative experience, and most attributed long-term positive changes in life satisfaction and purpose. The study also revealed vivid memories of the encounter, with many participants reporting communication with a conscious entity and decreased fear of death.
Researchers found that treating patients with personalized, combination therapies improved response rates and overall survival in patients with therapy-resistant cancers. Highly matched patients showed a 50% response rate compared to unmatched or less well-matched patients.
Researchers have identified three medicinal plants from Mauritius with effective inhibitors of esophageal cancer cells, stopping their growth and contributing to their death. The extracts contain natural chemical compounds that restrain the G2/M stages transition in malignant tumor cells by activating AMPK signaling pathway.
Researchers have developed a blood test that can identify genetic faults in cancer patients' blood, enabling clinicians to select targeted treatment options. The study showed that 11 out of 100 patients were successfully matched with molecularly matched clinical trials.
New research finds elevated levels of fatty acid transporter protein 2 (FATP2) in immune-suppressing cells, which can slow tumor growth and aid cancer treatments. The study also discovered an energy-granting lipid that FATP2 produces and traffics into cells, leading to its potential as a therapeutic target.
Research reveals that T-regulatory cells, which suppress the immune response, are driving tumor resistance to radiotherapy. Inhibiting EphB4-ephrinB2 interaction reduces T-reg cell activity, allowing immune cells to target cancer effectively.
A consortium of researchers identified a rare but important gene target, NRG1, responsible for development of various cancer types. The study suggests that targeting this gene fusion could effectively shut down cancers, offering a new therapy possibility.
Researchers combined CRISPR with drug discovery to understand how AML treatment works and which weaknesses can be exploited. The study revealed that LSD1-GFI1B relationship is critical for AML survival, enabling more targeted treatments.
Researchers have discovered that small molecule compounds can alter the spatial organization of the genome, potentially leading to new epigenetic cancer drugs. This breakthrough opens up a promising approach to treat cancer by changing the 3D genome structure.
Scientists successfully blocked cancer-fighting gene silencing protein UHRF1, restoring hundreds of protective genes in human colon cancer cells. The findings suggest a new strategy for fighting cancers by targeting this protein.
Researchers discovered that cancer cells can hide from immunotherapy by altering the levels of a key molecule on their surface. However, they identified an existing inhibitor of the WNT pathway that could potentially reverse this process and make cancer cells more visible to immune cells.
One-third of cancer patients use complementary and alternative medicines such as meditation, yoga, acupuncture, and herbal supplements. Many patients do not disclose their use to doctors due to lack of knowledge or perceived need for disclosure.
A nationwide survey found that 33.3% of cancer patients used complementary and alternative medicines, with herbal supplements being the most common. Many participants did not disclose their CAM use due to lack of physician inquiry or perceived unnecessary information.
Researchers at USC and UCLA have developed a new method to prevent damage to the jaw, a side effect of cancer treatment. The approach uses a different BP compound that can be used locally in the mouth to push the drug from the jawbone while leaving the useful drug undisturbed.
Researchers have identified chromogranin A as a key regulator of cardiotoxic and antitumor activities of Doxorubicin, a widely used cancer drug. Monitoring plasma levels of CgA before and after chemotherapy may provide prognostic information on drug-related cardiotoxicity.
Researchers used CRISPR technology to disrupt every gene in over 300 cancer models from 30 cancer types, discovering thousands of key genes essential for cancer's survival. The team developed a system to prioritize and rank 600 drug targets promising for development into targeted cancer treatments.
Cancer cells dependent on WRN enzyme to survive due to DNA repair system loss; MSI signature identified as effective biomarker for vulnerable tumors.
Researchers at UCSF have developed a new screening system to identify effective cancer-killers when combining drugs that are only partially effective as single-agent therapies. The study identified combinations of PI3K inhibitors and RNAi that eradicated a devastating blood cancer and certain solid tumor cells.
A comprehensive SWOG Cancer Research Network study has identified a host of targets for new or existing cancer drugs. The research, published in the Journal for ImmunoTherapy of Cancer, found higher counts of cancer-fighting TILs in pre-treatment tissue samples of breast cancer patients who achieved complete response to chemotherapy.
A recent study published in Nature Metabolism identified a novel pathway regulating drug tolerance in non-small-cell lung cancers with a specific mutation. MicroRNA miR-147b was found to mediate resistance to EGFR-based treatments, suggesting a potential new approach for treatment of lung cancer.
A USC study found that despite substantial media attention, most cancer drugs in shortage had little to no effect on chemotherapy treatment. Researchers analyzed over 2.4 million claims and found minimal change in treatment for the majority of oncology drugs during shortages.
A telerehabilitation program has been shown to improve the physical function, pain, and quality of life of patients with late-stage cancers. The study found that these patients who received remotely delivered rehabilitation services had fewer hospital and nursing home stays.
Researchers at Harvard Medical School and Dana-Farber Cancer Institute identify key molecules supporting lung cancer cell survival, demonstrating simultaneous inhibition of two signaling pathways. This approach could aid in designing drugs that selectively attack multiple proteins, beneficial for managing certain tumors.
A recent study in animal models of diffuse intrinsic pontine glioma (DIPG) has identified an experimental drug that effectively destroys DIPG cells by depleting cellular cholesterol. The researchers also found that the compound works by directly inhibiting lanosterol synthase, an enzyme involved in cholesterol production.
Researchers discovered that adiponectin, a hormone secreted by fat cells, protects female mice from liver cancer. In contrast, increased testosterone levels in male rodents reduce tumor growth and lower adiponectin levels.
Professor Jonas Bergh is recognized for his work on breast cancer biology, including tailored treatments and the impact of chemotherapy. He has made significant contributions to primary breast cancer treatment through his involvement in clinical trials and research collaborations.
Salk scientists discovered a new mechanism of action for the CDK12 protein, revealing its role in regulating gene expression and cell division. This finding suggests that targeting CDK12 could be an effective way to kill cancer cells and improve treatment outcomes.
Dr. Carl June receives the 2019 Harrington Prize for his contributions to CAR T therapy, a revolutionary cancer treatment. The prize honors his development of new strategies and culture systems that have enabled CAR T clinical trials.
A Phase II trial at MD Anderson Cancer Center showed umbralisib to be an effective treatment for patients with relapsed marginal zone lymphoma, achieving a 55% partial or complete response rate. The drug was well-tolerated, with a 71% progression-free survival after one year.
A new study by University of Pittsburgh researchers has identified a previously unknown mechanism used by tumors to suppress the immune system. The study found that tumors use two types of immune cells, regulatory T cells (Tregs), to release inhibitory cytokines, which activate a protein called BLIMP1 and disable killer T cells.
Early results from the UNITY-NHL phase II clinical trial show umbralisib to be highly active against relapsed/refractory marginal zone lymphoma, with a 55% partial or complete response rate and 71% progression-free survival at 12 months.
Researchers found that combining adavosertib with irinotecan, navitoclax or capecitabine increased its effectiveness against pancreatic cancer. The study aimed to identify new combinations of drugs to enhance adavosertib's effect.
Researchers found tarloxotinib effective against various cancer types, including ovarian and breast cancers with NRG1 gene fusions. The drug targets low-oxygen conditions, making it potentially more tolerable than existing therapies.
A University of Colorado Cancer Center study identifies a compound that inhibits the action of the SIX1/EYA transcriptional complex, which is involved in cancer metastasis. The compound dramatically suppresses breast cancer-associated metastasis in mouse models.
A combination of ipilimumab and nivolumab has been shown to shrink tumors in patients with high-grade neuroendocrine carcinoma by 42 percent, while all low-grade patients did not see a response.
Researchers found that the medicine DFMO not only blocks cell growth but also directly targets H. pylori to reduce its virulence. This could lead to a new strategy for preventing stomach cancer. The study supports further research into using DFMO to prevent stomach cancer.
Researchers have developed an experimental combined drug therapy that dramatically shrinks tumours and prevents metastasis in mice by targeting the DNA repair capability of cancer cells. The treatment has few side-effects compared to traditional chemotherapy and is being tested in clinical trials.
A national survey found that 81% of hospital pharmacy managers experienced medication hoarding due to drug shortages, with over two-thirds reporting more than 50 shortages. The survey highlights the need for more systematic approaches to address the issue and decrease rationing.
Researchers at Sanford Burnham Prebys have created a mouse model of choroid plexus carcinoma (CPC), a challenging type of brain cancer that affects young children. The study identified three promising drug compounds with biological activity, including dinaciclib and flavopiridol.
Researchers at Johns Hopkins Medicine have developed a new technique using PET scans to track the interaction between cancer drugs and tumor cells, providing valuable insights into how effective treatment is. This breakthrough could streamline cancer therapy by enabling doctors to tailor treatments, determine therapeutic doses, and avo...
Researchers will compare DNA from sepsis patients who died and survived to isolate signals and identify future drug targets. The study, funded by Sepsis Research, aims to better understand how genes govern sepsis recovery.
Researchers identified a critical protein for tumor cell survival and found that targeting it could be a novel treatment strategy for MSI-H tumors. The study suggests that pharmacological inhibition of WRN function might serve as a targeted therapeutic approach.
A new study finds that preventive medications, such as those for blood pressure and bone health, are frequently continued until death in older adults with cancer. The use of these medications can increase the risk of serious side effects and reduce quality of life.
A new study found that replacing a half hour of sitting time with light physical activity was associated with a nearly 50% reduction in mortality among the least active participants. Replacing sedentary time with moderate-intensity physical activity was also linked to a lower risk of death, although the association was smaller.
Researchers found that mda-7/IL-24 reduces the expression of an enzyme called DICER, which processes microRNAs for specific cellular functions. This effect occurs only in cancer cells and provides potential therapeutic targets for cancer treatment.
Researchers say gene interactions are key to understanding disease risk and treatment response, but current methods lack statistical power to uncover multiple genes. Genome-wide association studies have identified thousands of mutations that contribute to disease, but environmental effects and genetic diversity complicate matters.
Researchers have found that modulating blood-forming stem cells' stiffness could help drive them out of the bone marrow and into the blood, but they need to be stiff to stay put. The study, published in Cell Stem Cell, suggests that altering cell biomechanics can improve mobilization regimens for stem cell-based therapy.
Researchers at City of Hope have been awarded $7.5 million to develop new treatments for CTCL, a disfiguring and incurable cancer affecting about 3,000 individuals annually. The grant will support the development of personalized medicine and immunotherapy treatments.
The collaboration identifies leadership, patient engagement, and community engagement as crucial factors in increasing accrual of racial and ethnic minorities in cancer trials. High-recruiting centers like Henry Ford Cancer Institute excel in engaging providers, building trust, and seeking input from minority patients and caregivers.
Researchers found that cancer cells with fewer mitochondria are more likely to respond to certain drug treatments, offering a new avenue for targeted therapies. The study's findings suggest that enhancing understanding of the relationship between mitochondrial variability and drug response may lead to more effective cancer treatments.
Researchers at Oregon State University have patented a method for synthesizing cephalotaxine and homoharringtonine (HHT), previously only available from an Asian tree. This development paves the way for more readily available and affordable leukemia treatments.
Researchers have identified a promising new therapeutic strategy using two types of drug inhibitors to treat pancreatic cancer. The approach combines chloroquine with an inhibitor of the replication stress response pathway, showing potential in reducing tumor growth and improving prognosis.